Riskpilot← Back to searchSign inGet full accessElicera Therapeutics AB
ABActiveOrg 5569664955Mässans Gata 10 Vån 7Research and experimental development on natural sciences and engineering · NACE 7210Est. 20145-9 employees
Revenue 2024
SEK 7,1M
-37% vs 2023
EBITDA margin
-236.7%
+1% vs 2023
Equity ratio
75.3%
Financial strength
Net profit 2024
SEK -16,1M
+2% vs 2023
| Revenue | SEK 7,1M | -37% |
| EBITDA | SEK -16,9M | +1% |
| Net profit | SEK -16,1M | +2% |
| Total assets | SEK 27,6M | -9% |
| Equity | SEK 20,8M | +27% |
| Employees | — | — |
Legal name
Elicera Therapeutics AB
Org number
5569664955
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
26 mars 2014
Share capital
SEK 1 474 000
Employees
5-9
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas av Edberg, Eva Agneta i förening med en av ledamöterna Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva verksamhet inom Life Science samt därmed förenlig verksamhet.
Address
Mässans Gata 10 Vån 7
Phone
+46703449579
Email
info@elicera.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1 280 | 11 230 | 7 128 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −2 817 | −13 107 | −19 351 | −17 084 | −16 872 |
| Depreciation & amort. | −12 | −12 | −12 | −12 | −12 |
| EBIT | −2 829 | −13 119 | −19 363 | −17 096 | −16 884 |
| Net financials | 5 | −2 | −76 | 698 | 776 |
| Profit before tax | −2 823 | −13 120 | −19 439 | −16 398 | −16 110 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −2 823 | −13 120 | −19 439 | −16 398 | −16 110 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 12 590 | 54 738 | 46 308 | 30 180 | 27 567 |
| Equity | 10 236 | 52 238 | 32 799 | 16 401 | 20 770 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2 354 | 2 500 | 13 509 | 13 779 | 6 796 |
| Total debt | 2 354 | 2 500 | 13 509 | 13 779 | 6 796 |
EBITDA margin
-236.7%
This company
15.8%
Market median
-1598% vs market
20202024
Equity ratio
75.3%
This company
38.2%
Market median
+97% vs market
20202024
Return on equity
-77.6%
This company
18.4%
Market median
-522% vs market
20202024
Net profit margin
-226.0%
This company
8.1%
Market median
-2890% vs market
20202024
Asset turnover
0.26×
This company
1.12×
Market median
-77% vs market
20202024
Debt / equity
0.33×
This company
0.62×
Market median
+47% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
JE Chief Executive Officer | Chief Executive Officer | 2020 |
KI Chief Auditor | Chief Auditor | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (6) | ||
| Board of Directors | 2020 | |
| Chairman | 2020 | |
| Board of Directors | 2020 | |
| Board of Directors | 2020 | |
DY | Deputy Board Member | 2020 |
| Board of Directors | 2024 | |
| Former (2) | ||
| Board of Directors | 2021 – 2022 | |
| Board of Directors | 2020 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Elicera Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jamal El Mosleh | Chief Executive Officer | 0 companies |
| Kristofer Ingmar Håkansson | Chief Auditor | 0 companies |
| Karin Helene Hoogendoorn | Board of Directors | 0 companies |
| Margareth Birgitta Jorvid | Board of Directors | 0 companies |
| Eva Agneta Edberg | Chairman | 0 companies |
| Lars Magnus Essand | Board of Directors | 0 companies |
| Christina Elisabeth Herder | Board of Directors | 0 companies |
| Jan Gustaf Zetterberg | Board of Directors | 0 companies |
| Di Yu | Deputy Board Member | 0 companies |
| Sharon Jayne Longhurst | Board of Directors | 0 companies |